Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SORT-COPD
NCT06986070Phase 1Recruiting
- Sponsor
- SMSbiotech
- Start
- Jun 2025
- Primary completion
- Dec 2026
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label trial of small mobile stem cells in chronic obstructive pulmonary disease (COPD) (3 cohorts), sponsored by SMSbiotech. Primary endpoints: Adverse events at Month 6, Dose limiting toxicity at Month 6 and 1 more. Started Jun 2025; status: recruiting.
02
Drugs
small mobile stem cells
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT06986070.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06986070.